The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 68.50
Bid: 65.00
Ask: 72.00
Change: 6.00 (9.60%)
Spread: 7.00 (10.769%)
Open: 62.50
High: 68.50
Low: 62.50
Prev. Close: 62.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bleepa selected for WISH 2020 Innovation Awards

5 Nov 2020 07:01

RNS Number : 3026E
Feedback PLC
05 November 2020
 

 

Feedback plc

 

Bleepa selected for WISH 2020 Innovation Awards Programme

 

· World Innovation Summit for Health ("WISH") - 15-19 November 2020

· Named as a WISH 2020 Innovation Booster

· Year-long prestigious awards programme enables access to key Middle-East healthcare markets

 

London, 5 November 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that Bleepa has been selected as a WISH 2020 Innovation Booster at the World Innovation Summit for Health, 15-19 November 2020 in Doha, Qatar.

 

The WISH 2020 Innovation Booster

 

The WISH Innovation Booster provides a chance for entrepreneurs to exhibit their healthcare innovations in front of some of the world's leading health experts, health ministers, decision-makers, and investors. WISH provides a platform to enable delegates to engage with these cutting-edge ideas that are changing healthcare from the ground up.

 

The WISH 2020 Innovation Booster programme represents some of the world's most exciting healthcare innovations, ranging from practical devices and business models to design-based solutions. Companies showcasing their innovations share a common goal: driving improvement and excellence in healthcare. Each innovation showcase has the potential to transform global health, both reducing the costs of healthcare delivery and improving the quality of care for patients.

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"We are delighted to have been accepted for the prestigious virtual WISH programme which is a dedicated showcasing event into the Middle-Eastern healthcare markets. Every year, WISH selects a handful of products from around the world that it really wants to champion and promote, and it awards them a WISH fellowship, providing a year-long dedicated programme of support to launch those products into the Middle-Eastern market and we are proud to say that Bleepa has been chosen as one of their WISH 2020 Innovation Boosters. This represents a fantastic opportunity for us to really promote Bleepa into the Middle-East."

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

 

 

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

 

 

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

 

 

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

About WISH

 

We forge connections and help build action-driven communities of knowledge who work together to address today's most pressing global healthcare challenges.

 

We convene and collaborate with the world's leading experts and the highest levels of decision-makers.

 

We create and disseminate world-class, evidence-based content and knowledge.

 

We promote active learning and support within and between communities.

 

We contribute to the vision and mission of Qatar Foundation for Education, Science and Community Development and Qatar National Vision 2030, and serve to underscore Qatar's pioneering role as an emerging center for healthcare innovation.

 

We showcase innovations that will make a difference for healthcare communities everywhere.

 

We aim to influence healthcare policy globally.

 

https://2020.wish.org.qa/about-wish/

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXFLEANEFFA
Date   Source Headline
30th Jun 20172:21 pmRNSHolding(s) in Company
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.